ES2819217T3 - Conjugados de polímeros iónicos dipolares y factor VIII - Google Patents

Conjugados de polímeros iónicos dipolares y factor VIII Download PDF

Info

Publication number
ES2819217T3
ES2819217T3 ES14841835T ES14841835T ES2819217T3 ES 2819217 T3 ES2819217 T3 ES 2819217T3 ES 14841835 T ES14841835 T ES 14841835T ES 14841835 T ES14841835 T ES 14841835T ES 2819217 T3 ES2819217 T3 ES 2819217T3
Authority
ES
Spain
Prior art keywords
polymer
group
fviii
initiator
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14841835T
Other languages
English (en)
Spanish (es)
Inventor
Stephen A Charles
D Victor Perlroth
Li Song
Martin Linsell
Wayne To
Didier Benoit
James Aggen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kodiak Sciences Inc
Original Assignee
Kodiak Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kodiak Sciences Inc filed Critical Kodiak Sciences Inc
Application granted granted Critical
Publication of ES2819217T3 publication Critical patent/ES2819217T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
    • C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F120/10—Esters
    • C08F120/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
    • C08F120/36—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate containing oxygen in addition to the carboxy oxygen, e.g. 2-N-morpholinoethyl (meth)acrylate or 2-isocyanatoethyl (meth)acrylate
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/3332—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing carboxamide group
    • C08G65/33324—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing carboxamide group acyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Graft Or Block Polymers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES14841835T 2013-09-08 2014-09-08 Conjugados de polímeros iónicos dipolares y factor VIII Active ES2819217T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361875099P 2013-09-08 2013-09-08
PCT/US2014/054622 WO2015035342A2 (en) 2013-09-08 2014-09-08 Factor viii zwitterionic polymer conjugates

Publications (1)

Publication Number Publication Date
ES2819217T3 true ES2819217T3 (es) 2021-04-15

Family

ID=52629093

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14841835T Active ES2819217T3 (es) 2013-09-08 2014-09-08 Conjugados de polímeros iónicos dipolares y factor VIII

Country Status (11)

Country Link
US (3) US10702608B2 (2)
EP (2) EP3041513B1 (2)
JP (5) JP6463361B2 (2)
DK (1) DK3041513T3 (2)
ES (1) ES2819217T3 (2)
HU (1) HUE052447T2 (2)
LT (1) LT3041513T (2)
PL (1) PL3041513T3 (2)
PT (1) PT3041513T (2)
SI (1) SI3041513T1 (2)
WO (1) WO2015035342A2 (2)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
KR102799807B1 (ko) * 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2023067681A1 (ja) 2021-10-19 2023-04-27 株式会社日立ハイテク 荷電粒子線装置
WO2025184423A1 (en) * 2024-02-29 2025-09-04 Kodiak Sciences Inc. Cell-surface-targeting-domain-polymer-payload conjugate
WO2025190493A1 (de) 2024-03-15 2025-09-18 Alexander Wolf Pyrolyseanlage zum chargenweisen herstellen von pflanzenkohle durch pyrolyse von biomasse sowie verfahren

Family Cites Families (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5296363A (en) 1976-02-06 1977-08-12 Takamatsu Electric Works Ltd Device for supplementing gas in gas sealed distributing device
JPS5472168A (en) 1977-11-18 1979-06-09 Tiger Vacuum Bottle Ind Electric cooking implement
JPS5846044B2 (ja) 1979-04-14 1983-10-14 日本金属株式会社 圧粉鉄心
JPS5745009U (2) 1980-08-26 1982-03-12
JPS6337605Y2 (2) 1980-09-19 1988-10-05
JPS5846044U (ja) 1981-09-22 1983-03-28 桜井　幸雄 掘りごたつ
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
ATE72838T1 (de) 1985-04-12 1992-03-15 Genetics Inst Neue prokoagulierungsproteine.
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2147729T3 (es) 1991-01-31 2000-10-01 Cor Therapeutics Inc Dominios de la region extracelular de polipeptidos receptores de factor de crecimiento derivado de plaquetas humano.
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2144419T3 (es) 1991-07-05 2000-06-16 Biocompatibles Ltd Revestimientos polimericos de superficies.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DE69311329T2 (de) 1992-03-27 1998-01-08 Tidy Tea Ltd Verpackung für stoffe zur aufgussbereitung
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
DE69329795T2 (de) 1992-10-02 2001-07-05 Genetics Institute, Inc. Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
GB9301702D0 (en) 1993-01-28 1993-03-17 Biocompatibles Ltd New materials
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
GB9324033D0 (en) 1993-11-23 1994-01-12 Biocompatibles Ltd Ethylenically unsaturated compounds
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5681746A (en) 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US6541580B1 (en) 1995-03-31 2003-04-01 Carnegie Mellon University Atom or group transfer radical polymerization
US5763548A (en) 1995-03-31 1998-06-09 Carnegie-Mellon University (Co)polymers and a novel polymerization process based on atom (or group) transfer radical polymerization
KR19990064280A (ko) 1995-10-16 1999-07-26 존 바드웰 인 함유 화합물의 산화방법
GB9521234D0 (en) 1995-10-16 1995-12-20 Biocompatibles Ltd Synthesis of polymerisable phospho diesters
US5807937A (en) 1995-11-15 1998-09-15 Carnegie Mellon University Processes based on atom (or group) transfer radical polymerization and novel (co) polymers having useful structures and properties
US5663425A (en) 1996-01-26 1997-09-02 Lignotech Usa, Inc. Production of acid soluble humates
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5789487A (en) 1996-07-10 1998-08-04 Carnegie-Mellon University Preparation of novel homo- and copolymers using atom transfer radical polymerization
JPH10139832A (ja) 1996-11-08 1998-05-26 Nof Corp 共重合体およびグルコースセンサー
US7125938B2 (en) 1997-03-11 2006-10-24 Carnegie Mellon University Atom or group transfer radical polymerization
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
JP3052923B2 (ja) 1997-05-30 2000-06-19 日本油脂株式会社 （メタ）アクリレート誘導体の製造方法
ATE333114T1 (de) 1998-01-30 2006-08-15 Albemarle Corp Maleimide enthaltende fotopolymerisierbare zusammensetzungen und verfahren zu deren verwendung
JP4162284B2 (ja) 1998-02-04 2008-10-08 日油株式会社 洗浄剤組成物
US6121371A (en) 1998-07-31 2000-09-19 Carnegie Mellon University Application of atom transfer radical polymerization to water-borne polymerization systems
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6159942A (en) 1998-06-19 2000-12-12 Bioenergy, Inc. Compositions for increasing energy in vivo
JP4145403B2 (ja) 1998-09-29 2008-09-03 日油株式会社 免疫学的活性物質測定用高分子／酵素結合体
WO2000059968A1 (en) 1999-04-05 2000-10-12 The Research Foundation Of State University Of New York Graft, graft-block, block-graft, and star-shaped copolymers and methods of making them
FR2794459B1 (fr) 1999-05-19 2004-09-03 Atofina Polyalcoxyamines issues de nitroxydes beta-substitues
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
ATE407697T1 (de) 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
US7049373B2 (en) 1999-08-06 2006-05-23 Carnegie Mellon University Process for preparation of graft polymers
EP1222217B1 (en) 1999-09-08 2005-06-15 Polytherics Limited Uniform molecular weight polymers
US6348554B1 (en) 1999-11-30 2002-02-19 Rohmax Additives Gmbh Method for preparation of a liquid polymer composition and use of this composition
GB9928956D0 (en) 1999-12-07 2000-02-02 Malik Navid Internally supported biomimetic coating systems
US6852816B2 (en) 2000-10-06 2005-02-08 Biocompatibles Uk Limited Zwitterionic polymers
JP5005155B2 (ja) 2000-10-06 2012-08-22 カーネギー−メロン ユニバーシティ イオンモノマーの重合方法
WO2002028914A2 (en) 2000-10-06 2002-04-11 Carnegie Mellon University A catalyst system for controlled polymerization
AU2002211467A1 (en) 2000-10-06 2002-04-15 Carnegie-Mellon University Preparation of nanocomposite structures by controlled polymerization
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2002307151A1 (en) 2001-04-06 2002-10-21 Carnegie Mellon University A process for the preparation of nanostructured materials
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6780428B2 (en) 2001-06-08 2004-08-24 Labopharm, Inc. Unimolecular polymeric micelles with an ionizable inner core
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
EP1421376A2 (de) 2001-08-27 2004-05-26 Zeptosens AG Bionalytische erkennungsoberfläche mit optimierter dichte der erkennungselemente
JP2003064132A (ja) 2001-08-28 2003-03-05 Nof Corp 重合体、製造方法および乳化・分散剤
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US6759491B2 (en) 2001-10-12 2004-07-06 Carnegie Mellon University Simultaneous reverse and normal initiation of ATRP
WO2003031480A2 (en) 2001-10-12 2003-04-17 Carnegie Mellon University Process for monomer sequence control in polymerizations
AU2002352524B2 (en) 2001-11-07 2007-10-04 Nektar Therapeutics Branched polymers and their conjugates
ATE371680T1 (de) 2002-01-16 2007-09-15 Biocompatibles Uk Ltd Polymerkonjugate
US20050220880A1 (en) 2002-03-07 2005-10-06 Lewis Andrew L Drug carriers comprising amphiphilic block copolymers
AU2003217009A1 (en) 2002-03-07 2003-09-16 Biocompatibles Uk Limited Compositions of polymers
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7196142B2 (en) 2002-04-04 2007-03-27 The University Of Akron Polyisobutylene-based block anionomers and cationomers and synthesis thereof
JP4248189B2 (ja) 2002-04-09 2009-04-02 株式会社資生堂 ホスホリルコリン基含有多糖類及びその製造方法
WO2003099835A1 (en) 2002-05-21 2003-12-04 Emory University Multivalent polymers with chain-terminating binding groups
WO2004014963A2 (en) 2002-08-09 2004-02-19 Carnegie Mellon University Polymers, supersoft elastomers and methods for preparing the same
US20060165804A1 (en) 2002-09-25 2006-07-27 Lewis Andrew L Polymer compositions for administration to animals
JP2006505686A (ja) 2002-11-07 2006-02-16 ロディア・シミ 両性又は双極性イオン性部分を含む制御された構造のコポリマー
US20070111279A1 (en) 2002-11-13 2007-05-17 Procell, Inc. Production of recombinant therapeutic bioscavengers against chemical and biological agents
GB0301014D0 (en) 2003-01-16 2003-02-19 Biocompatibles Ltd Conjugation reactions
WO2004065418A1 (ja) 2003-01-20 2004-08-05 Chugai Seiyaku Kabushiki Kaisha 抗pci中和抗体
EP1590388A2 (en) 2003-02-05 2005-11-02 Biocompatibles UK Limited Block copolymers
RU2358763C2 (ru) 2003-02-10 2009-06-20 Элан Фармасьютикалз, Инк. Композиции иммуноглобулина и способ их получения
CA2521381C (en) 2003-04-11 2020-05-26 Rezolute, Inc. Method for preparation of site-specific protein conjugates
TR201907313T4 (tr) 2003-05-23 2019-06-21 Nektar Therapeutics İki PEG zinciri içeren PEG türevleri.
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
CN1208358C (zh) 2003-07-31 2005-06-29 上海交通大学 含多羟基官能团多臂星状超支化聚合物刷及其制备方法
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
ES2629696T3 (es) 2003-09-17 2017-08-14 Nektar Therapeutics Profármacos poliméricos multibrazo
ATE555133T1 (de) 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
EP2905033B1 (en) 2003-12-16 2020-09-02 Nektar Therapeutics Monodisperse PEGylated naloxol compositions
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
KR100593443B1 (ko) 2004-02-11 2006-06-28 삼성전자주식회사 트랜지스터들 및 그 제조방법들
JP4727938B2 (ja) 2004-02-24 2011-07-20 泰彦 岩崎 リビングラジカル重合開始基を持つポリリン酸の製造方法および用途
WO2005087808A2 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Growth factor binding constructs materials and methods
JP4727941B2 (ja) 2004-03-12 2011-07-20 泰彦 岩崎 生分解性重合体の製造方法および用途
US20050208093A1 (en) 2004-03-22 2005-09-22 Thierry Glauser Phosphoryl choline coating compositions
GB0412181D0 (en) * 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US7863238B2 (en) 2004-06-10 2011-01-04 Saint Louis University Proteins with an attached short peptide of acidic amino acids
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
KR101468345B1 (ko) 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
US7214759B2 (en) 2004-11-24 2007-05-08 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on polyesters and methods for fabricating the same
WO2006063055A2 (en) 2004-12-06 2006-06-15 Bolder Biotechnology, Inc. Enzyme conjugates for use as detoxifying agents
EP1838349A1 (en) 2004-12-15 2007-10-03 Neuralab, Ltd. Amyloid beta antibodies for use in improving cognition
ATE369486T1 (de) 2004-12-18 2007-08-15 Haldor Topsoe As Verfahren zur regelung der zugabe eines reduktionsmittels in das abgas einer brennkraftmaschine
CA2600601A1 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Anti-m-csf antibody compositions having reduced levels of endotoxin
US20060234347A1 (en) 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
WO2006118547A1 (en) 2005-04-29 2006-11-09 Agency For Science, Technology And Research Hyperbranched polymers and their applications
US20070005130A1 (en) 2005-06-29 2007-01-04 Thierry Glauser Biodegradable polymer for coating
WO2008020827A2 (en) 2005-08-01 2008-02-21 Biogen Idec Ma Inc. Altered polypeptides, immunoconjugates thereof, and methods related thereto
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
CN101379091B (zh) 2005-08-26 2012-05-30 卡内基梅隆大学 在催化剂再生下的聚合方法
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
US7906134B2 (en) 2005-12-21 2011-03-15 Abbott Laboratories Room temperature-curable polymers
DE102006009004A1 (de) 2006-02-23 2007-09-06 Sustech Gmbh & Co. Kg Multifunktionelle sternförmige Präpolymere, deren Herstellung und Verwendung
DK1988910T3 (en) 2006-02-28 2018-01-22 Kodiak Sciences Inc ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE-CONTAINING POLYMER CONJUGATES AND PREPARATION thereof
JP2007263935A (ja) 2006-03-30 2007-10-11 Canon Inc 磁性マーカー及びその製造方法
EP2010584A4 (en) 2006-04-14 2010-07-21 Interface Biologics Inc DIPPLETED POLYMERS AND APPLICATIONS THEREOF
JP5030036B2 (ja) 2006-05-23 2012-09-19 一彦 石原 生体成分固定化ポリマー組成物および三次元架橋体
EP2038320B1 (en) 2006-06-29 2014-03-12 Life Technologies AS Particles containing multi- block polymers
US20080008736A1 (en) 2006-07-06 2008-01-10 Thierry Glauser Random copolymers of methacrylates and acrylates
JP5179487B2 (ja) 2006-07-14 2013-04-10 バイオコンパティブルズ ユーケー リミテッド ポリマー
KR100808116B1 (ko) 2006-08-22 2008-03-03 전남대학교산학협력단 미생물 점착 방지용 공중합체 수지 코팅재
WO2008025856A2 (en) 2006-09-01 2008-03-06 Novo Nordisk Health Care Ag Modified glycoproteins
JP5111016B2 (ja) 2006-11-01 2012-12-26 三井化学株式会社 表面親水性ポリオレフィン成形体およびその製造方法
EP2097119A4 (en) 2006-11-21 2012-10-17 Abbott Lab USE OF A TERPOLYMER OF TETRAFLUOROETHYLENE, HEXAFLUORPROPYLENE AND VINYLIDENE FLUORIDE IN MEDICAMENTAL COATINGS
WO2008070593A2 (en) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
US7651527B2 (en) 2006-12-15 2010-01-26 Medtronic Vascular, Inc. Bioresorbable stent
CA2674608A1 (en) 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
MX2009008132A (es) 2007-02-01 2009-08-12 Genentech Inc Terapia de combinacion con inhibidores de angiogenesis.
EP2118150B1 (en) 2007-02-14 2015-09-23 Biocompatibles UK Limited Derivatisation of biological molecules
CN101631568B (zh) 2007-03-12 2012-08-22 尼克塔治疗公司 低聚物-蛋白酶抑制剂偶联物
KR101561707B1 (ko) 2007-03-12 2015-10-19 넥타르 테라퓨틱스 올리고머―항히스타민제 컨주게이트
CN101053681B (zh) 2007-04-10 2010-05-19 天津大学 用于血管栓塞材料的温敏性MPC-b-NIPAM二嵌段星型共聚物及制备方法和应用
MX2009011226A (es) 2007-04-17 2010-04-01 Imclone Llc Inhibidores especificos pdgfrbeta.
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2160193A4 (en) 2007-05-14 2010-12-01 Tyco Healthcare COPOLYMERS OF FURANONE
JP5019524B2 (ja) 2007-06-01 2012-09-05 国立大学法人 東京大学 新規ポリ（メタ）アクリレート共重合体ならびに小胞体及びゴルジ体への送達方法
ATE502114T1 (de) 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
JP2009042617A (ja) 2007-08-10 2009-02-26 Canon Inc 静電荷像現像用トナー及びその製造方法
US7943370B2 (en) 2007-08-23 2011-05-17 Canon Kabushiki Kaisha Structure, target substance detection element and target substance detection kit
MX2010003718A (es) 2007-10-19 2010-04-21 Genentech Inc Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo.
JP5314033B2 (ja) 2007-10-22 2013-10-16 メルク セローノ ソシエテ アノニム 突然変異ＩｇＧＦｃフラグメントと融合した単一ＩＦＮ−ベータ
JP2009114283A (ja) 2007-11-05 2009-05-28 Asahi Kasei Chemicals Corp 吸引用シートおよびそれを用いた装置
EP2226075A1 (en) 2007-11-22 2010-09-08 The University of Tokyo Material for preventing tissue adhesion and material for preventing joint contracture
JP2011509675A (ja) 2008-01-18 2011-03-31 メディミューン，エルエルシー 部位特異的コンジュゲーションのためのシステイン操作抗体
JP5575116B2 (ja) 2008-05-15 2014-08-20 ビオコムパトイブルエス ユーケー リミテド 細胞内抗体送達
JP5344420B2 (ja) 2008-05-15 2013-11-20 独立行政法人国立循環器病研究センター 遺伝子導入剤及びその製造方法並びに核酸複合体
US8187623B2 (en) 2008-06-25 2012-05-29 Boston Scientific Scimed, Inc. Medical copolymers
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
JP2010117189A (ja) 2008-11-12 2010-05-27 Sumitomo Bakelite Co Ltd 生理活性物質固定化用基板
CN102317332B (zh) 2008-12-12 2014-04-30 马萨诸塞大学 两性离子聚合物
US8822610B2 (en) 2008-12-22 2014-09-02 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US20100158850A1 (en) 2008-12-23 2010-06-24 The Regents Of The University Of Michigan Dendrimer based modular platforms
WO2010111625A1 (en) 2009-03-27 2010-09-30 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
EP3028707A1 (en) 2009-05-01 2016-06-08 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
CN101575402B (zh) 2009-05-31 2012-06-27 中国科学院化学研究所 一种多臂星型聚合物及其制备方法
DK2260873T3 (da) 2009-06-08 2019-09-16 Biocompatibles Uk Ltd Pcylering af proteiner
PE20120622A1 (es) 2009-06-17 2012-05-26 Abbott Biotherapeutics Corp Anticuerpos anti-vegf y sus usos
AU2010270979B2 (en) 2009-06-22 2015-04-23 Medimmune, Llc Engineered Fc regions for site-specific conjugation
CN102025901A (zh) 2009-09-23 2011-04-20 国基电子（上海）有限公司 相机模组及其检测方法
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
US20120282211A1 (en) 2009-11-24 2012-11-08 Carnegie Mellon University Antibodies and conjugates for modulators of angiogenesis
JP5818805B2 (ja) 2009-12-11 2015-11-18 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ−ｃ抗体及びその使用方法
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
CN105153313A (zh) 2010-02-16 2015-12-16 诺沃—诺迪斯克有限公司 因子viii融合蛋白
US20130040888A1 (en) 2010-02-16 2013-02-14 Novo Nordisk A/S Factor VIII Molecules With Reduced VWF Binding
JP2013534931A (ja) 2010-04-15 2013-09-09 オリガシス 高分子量双性イオン含有重合体
JP2012025820A (ja) 2010-07-21 2012-02-09 Kansai Paint Co Ltd 親水化処理剤組成物
US9065060B2 (en) 2011-01-17 2015-06-23 Lg Chem, Ltd. Compound and organic light-emitting device comprising same
WO2012145746A1 (en) 2011-04-21 2012-10-26 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of neuromyelitis optica
WO2013040501A1 (en) 2011-09-16 2013-03-21 Pharmathene, Inc. Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
WO2013059137A1 (en) * 2011-10-17 2013-04-25 Oligasis High molecular weight zwitterion-containing polymers
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
WO2013152020A1 (en) 2012-04-03 2013-10-10 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor bb antibodies and uses thereof
JP5846044B2 (ja) 2012-05-23 2016-01-20 日油株式会社 （メタ）アクリル酸誘導体の製造方法
JP6234064B2 (ja) 2012-05-23 2017-11-22 キヤノン株式会社 重合体、前記重合体を用いた核磁気共鳴分析用または磁気共鳴イメージング用の造影剤、化合物、前記重合体を用いた核磁気共鳴分析方法および磁気共鳴イメージング方法
CN104704118A (zh) 2012-10-15 2015-06-10 诺和诺德保健Ag（股份有限公司） 凝血因子vii多肽
RU2692652C2 (ru) 2013-03-13 2019-06-25 Джензим Корпорейшн Слитые белки, содержащие связывающие pdgf и vegf части, и способы их применения
CN103193819A (zh) 2013-03-13 2013-07-10 苏州蔻美新材料有限公司 一锅法合成mpc的方法
SG11201509982UA (2) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
CN103421039B (zh) 2013-09-03 2015-12-23 重庆工商大学 2-甲基丙烯酰氧基乙基磷酰胆碱的合成方法
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MX379491B (es) 2014-06-28 2025-03-10 Kodiak Sciences Inc Antagonistas duales de factor de crecimiento derivado de plaquetas (pdgf)/factor de crecimiento endotelial vascular (vegf)
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4146168A4 (en) 2020-05-08 2024-06-12 Kodiak Sciences Inc. USE OF IL-6 ANTIBODIES AND VEGF TRAPS AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
EP4649959A2 (en) 2021-04-14 2025-11-19 Kodiak Sciences Inc. Methods of treating an eye disorder
AU2023217074A1 (en) 2022-02-10 2024-08-15 Kodiak Sciences Inc. Methods of purifying a product

Also Published As

Publication number Publication date
JP6732056B2 (ja) 2020-07-29
JP2020183404A (ja) 2020-11-12
EP3760639C0 (en) 2025-10-22
WO2015035342A3 (en) 2015-04-30
US20200261590A1 (en) 2020-08-20
JP2025165944A (ja) 2025-11-05
PT3041513T (pt) 2020-09-07
HUE052447T2 (hu) 2021-04-28
JP2023029851A (ja) 2023-03-07
EP3041513A4 (en) 2017-04-12
EP3760639A1 (en) 2021-01-06
US12214044B2 (en) 2025-02-04
JP7767260B2 (ja) 2025-11-11
SI3041513T1 (sl) 2020-11-30
JP6463361B2 (ja) 2019-01-30
DK3041513T3 (da) 2020-10-26
EP3041513B1 (en) 2020-08-05
JP7232796B2 (ja) 2023-03-03
US20160199501A1 (en) 2016-07-14
US11590235B2 (en) 2023-02-28
EP3760639B1 (en) 2025-10-22
US20230173081A1 (en) 2023-06-08
PL3041513T3 (pl) 2021-01-25
JP2016530302A (ja) 2016-09-29
WO2015035342A2 (en) 2015-03-12
JP2019081765A (ja) 2019-05-30
US10702608B2 (en) 2020-07-07
LT3041513T (lt) 2020-11-25
EP3041513A2 (en) 2016-07-13

Similar Documents

Publication Publication Date Title
ES2819217T3 (es) Conjugados de polímeros iónicos dipolares y factor VIII
ES2623677T3 (es) Forma de sal de un producto conjugado de polímero-fármaco multibrazo
ES2875426T3 (es) Compuestos de hormona de crecimiento humana recombinante pegilada
JP5687752B2 (ja) オリゴマー−プロテアーゼ阻害剤複合体
ES2536450T3 (es) Conjugados que tienen una unión degradable y reactivos poliméricos útiles en la preparación de tales conjugados
ES2242396T3 (es) Conjugados de analogos de peg-lhrh.
US10413614B2 (en) Conjugates for protection from nephrotoxic active substances
CA2854361A1 (en) Subcutaneous delivery of polymer conjugates of therapeutic agents
WO2011042450A1 (en) Carrier linked paliperidone prodrugs
CN106232131A (zh) 生长抑素和其类似物的结合物
US20250313579A1 (en) Ligand compounds comprising a chelating group as a bridging group
TW200426155A (en) Activated polyethylene glycol esters
HK40043414A (en) Zwitterionic polymer conjugates
HK40043412A (en) Zwitterionic polymer conjugates
BR112024008991B1 (pt) Conjugado de derivado de poli(e-l-lisina)-fármaco, e, composto
HK40108784A (zh) 控释pth化合物的剂量方案
BR112018011152B1 (pt) Agonistas de cnp de liberação controlada